Travere reports Q3 2026 results, FILSPARI sales climb as pipeline advancesNov 2Quarterly updatepegtibatinasesparsentan
Travere Therapeutics names Bradley Campbell CEO as Eric Dube exitsSep 21PeopleTravere Therapeutics, Inc.
Travere reports Q2 2026 results as FSGS launch begins and civorebrutinib deal closesAug 4Quarterly updatepegtibatinasesparsentan
Travere's chief accounting officer to retire, controller named as successorJul 9PeopleTravere Therapeutics, Inc.